Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: January 5, 2007
Last updated: May 15, 2009
Last verified: May 2009
The proposed study is designed to investigate the pharmacokinetics, pharmacodynamics (as measured by serum cortisol) and safety of GW685698X in subjects with moderate hepatic impairment and in healthy subjects following a single oral inhaled dose of GW685698X. From the study results it should be possible to assess if there is an altered Risk: Benefit in patients with moderate hepatic impairment

Condition Intervention Phase
Hepatic Impairment
Drug: GW685698X
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study to Investigate the Pharmacokinetics of a Single Inhaled Dose (400mcg) of GW685698X and Its Effect on Serum Cortisol in Patients With Impaired Liver Function and Matched Control Subjects.

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • To investigate how impaired liver function affects the movement of single dose inhaled drug GW685698X within the body. Blood exposure levels in patients and matched control patients compared by taking blood samples after dosing

Secondary Outcome Measures:
  • Effect of GW685698X on serum cortisol by calculating weighted mean in blood over 24 hrs. Safety and tolerability of GW685698X in patients with impaired liver function from blood samples during dosing (clearance/distribution) and monitoring vital signs

Estimated Enrollment: 20
Study Start Date: January 2005

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes


  • Are aged between 18-70 years, inclusive.
  • If Female, you must be incapable of becoming pregnant.
  • Show FEV1 of more than 70% of the predicted normal at screening.
  • Are able to correctly use a DISKUS at the screening visit.
  • Have Body Mass Index within the range of 19-33 kg/m2 inclusive.
  • Do not show a positive pre-study urine drug screen.
  • Do not show a positive pre-study blood alcohol test.
  • Demonstrate a clinically normal 12-lead ECG at screening.
  • Do not show a positive blood test for HIV.

If you are a Healthy Volunteer you must also:

  • Have no significant abnormality on clinical examination.
  • Have Liver Function Tests within the reference range at screening.

If you are a Patient Volunteer you must:

  • Have moderate hepatic impairment
  • Have no significant abnormality on clinical examination apart from hepatic impairment.


  • Suffered an upper respiratory infection in the 4 weeks before the screening visit.
  • Suffered a lower respiratory infection in the 6 weeks before the screening visit.
  • Taken oral corticosteroids in the 8 weeks before the screening visit.
  • Taken inhaled, intranasal or topical steroids in the 4 weeks before the screening visit.
  • A prolonged heartbeat (QTc interval >470msec).
  • High blood pressure (systolic >160mmHg or diastolic >90mmHg) or as defined by the Investigator.
  • Known sensitivity to corticosteroids.
  • A history of lactose intolerance.
  • A history of severe milk protein allergy.
  • Donated blood in the last 3 months, or more than 1500mL (1000mL if female) in the last 12 months (including the amount taken for this study).
  • Participated in a clinical trial within the last 3 months where you are/were exposed to a drug or device.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00419237

Sponsors and Collaborators
Study Director: GSK Clinical Trials, MD MDsc FFPM GlaxoSmithKline
  More Information

Responsible Party: Study Director, GSK Identifier: NCT00419237     History of Changes
Other Study ID Numbers: FFA10013 
Study First Received: January 5, 2007
Last Updated: May 15, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by GlaxoSmithKline:
hepatic impairment pharmacokinetics

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases processed this record on August 28, 2016